Skip to content

Study of the Application of CPAP to Reduce Complications and Improve Lung Cancer Ablation Radiofrequency Treatment

Application of CPAP to Reduce Complications and Improve Treatment of Radiofrequency Ablation of Lung Cancer Under Conscious Sedation. A Randomized Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02117908
Acronym
CPAP-RFP
Enrollment
47
Registered
2014-04-21
Start date
2014-11-30
Completion date
2018-02-21
Last updated
2018-07-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atelectasis, Lung Cancer

Keywords

prevention, radiofrequency treatment, lung cancer ablation

Brief summary

The project aims to study whether the application of a continuous positive airway pressure (CPAP) of 4 cm water vapor is a safe method in pulmonary radiofrequency intervention (PRF) lung cancer under conscious sedation compared with placebo. And, assess whether CPAP prevents atelectasis formation and consequently reduces the potential complications of PRF and improves procedural success

Interventions

DEVICERESMED AUTOSET S9

Continuous positive pressure during surgery

Sponsors

Ministerio de Economía y Competitividad, Spain
CollaboratorOTHER_GOV
Sara Varea
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* male and female aged 18 years and older * Patient with a scheduled intervention for ablation of pulmonary malignant tumor with radiofrequency . * Patient able to undergo tests and examinations required by the study.

Exclusion criteria

* Patients with CPAP intolerance test. * Patients with progressive disease in which local treatment is not applicable * Patients with intercurrent process (pleural effusion, pneumonia, ...). * Patient unable to understand the proceedings. * Pregnancy or breastfeeding.

Design outcomes

Primary

MeasureTime frameDescription
Number of Participants with Adverse Events as a Measure of Safetythirty daysPatients with any of the following complications Pulmonary over-distention along intervention Pneumothorax along intervention Bronchial fistulas measures Computed tomography (CT)1, CT2 and CT3 Vomiting along intervention Decrease in MAP (mean arterial pressure) \> 20% measured in the intraoperative period Assay of each of the previous complications

Secondary

MeasureTime frameDescription
Prevention of atelectasis.during surgeryAtelectasic area Normal ventilation pulmonary area Hypoventilation pulmonary area Hyperventilation pulmonary area Bronchial wall injury distance
Decrease associated complications with PFR. Measurement times: intraoperative, PACU (post-anesthesic care unit), hospital discharge, day 15 and day 30.thirty daysMajor complications (death, failure to complete treatment, need for manual ventilation, intubation or resuscitation, pulmonary hemorrhage, need for pleural drainage, shock, fistulas, nerve injury, diaphragmatic injury, persistent pain, infections, increased hospitalization time and readmission rates) and any classified as a serious adverse event.
Treatment successMeasurement time: CT3Tumor ablation range, measured in CT3.
Predictors factors of the occurrence of complications during PRA (pulmonary radiofrequency ablation).thirty daysMinor complications (transient episodes of hypoxemia, apnea / hypoventilation or hypotension, pneumothorax without clinic symptoms or drainage, increased need for sedation, longer procedure) and any other event adverse not classified as serious.

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 7, 2026